AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

Shares of Summit Therapeutics jumped 9% Thursday on a report that it was discussing a lucrative partnership deal with ...

UK pharma major AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal ...

A large, well-capitalized peer is apparently interested in a partnership deal with the company. The media outlet in question ...

Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on ...

AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ...

It might be gearing up to pay billions of dollars to participate in a drug program currently in development. AstraZeneca ...

-- AstraZeneca is in talks with Summit Therapeutics for a deal in which it could pay as much as $15 billion over time to license a lung-cancer drug, Bloomberg reported Thursday, citing people familiar ...

Composite PMI in the United Kingdom increased to 52 points in June from 50.30 points in May of 2025. Germany (DAX:IND) +0.23% ...

Intel’s mooted plan to push key foundry work from its coming 18A manufacturing node to a later 14A process would not meaningfully affect earnings over the next two years, Morgan Stanley (NYSE:MS) said ...